お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
972020

ワクチン販売市場(2020年~2030年):疾患タイプ、ウイルス性疾患、細菌性疾患、ワクチンタイプ、流通チャネル、年齢層、地域別の予測、競合情勢、COVID-19影響分析、大手企業のプロファイル

Vaccines Sales Market Report 2020-2030: Forecasts by Disease Type, Viral Diseases, Bacterial Diseases, Type of Vaccines, Distribution Channel, Age Group, Region, Competitive Landscape, COVID-19 Impact Analysis, Profiles of Leading Companies

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 602 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=144.98円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ワクチン販売市場(2020年~2030年):疾患タイプ、ウイルス性疾患、細菌性疾患、ワクチンタイプ、流通チャネル、年齢層、地域別の予測、競合情勢、COVID-19影響分析、大手企業のプロファイル
出版日: 2020年09月10日
発行: Visiongain Ltd
ページ情報: 英文 602 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートは、世界のワクチン販売市場について調査しており、市場規模や予測、機会、成長および抑制要因、疾患タイプ・ウイルス性疾患・ワクチンタイプ・細菌性疾患・流通チャネル・年齢層・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

  • 市場を支配する細菌タイプの需要の高まり
  • 年齢層別分析
  • 流通チャネル分析別
  • 地域市場の洞察

第3章 ワクチン業界の概要

  • 業界の定義
  • 免疫システムとワクチン
  • ワクチンのしくみ
  • イミュニティのタイプ
    • 獲得免疫
    • 受動免疫
    • 予防接種の利点
  • ワクチンの歴史
  • パンデミックのためのラピッドマニュファクチャリング
    • ワクチン製造方法タイプ

第4章 市場力学

  • COVID-19パンデミックの中でのワクチンの開発と流通
  • 成長要因
    • 予防接種プロセスを支援するユニセフ、WHO、PAHOによるワクチン供給の増加
    • 研究開発に裏打ちされた強力な供給
    • 予測期間中に市場売上を拡大する競合のパイプライン
    • ラピッドマニュファクチャリングなどの技術進歩
    • 世界における予防接種の増加
    • ワクチン開発に対する政府の支援
  • 抑制要因
    • 採用を制限するワクチン投与に関連する高いコスト
    • 低所得国における認識の欠如
    • ワクチンの高い価格
    • 関連するリスク要因への懸念の高まり
    • 不十分なワクチン供給
  • 世界市場での成長機会
    • RNAワクチン接種
    • 抗生物質耐性の上昇
    • 現在の状況
    • 新しいワクチンの開発と発売
    • 研究開発努力の増加
    • 新興市場からの需要増加
    • 予防接種を増やすための政府のイニシアチブ
    • ワクチンと予防接種のための世界のアライアンス(GAVI)
    • 持続可能な予防接種サービスへのアクセスの改善
    • 起伏のある需要
    • 供給制限
    • 資金調達の動向
    • 経済労働力の保護
  • SWOT分析
  • STEP分析

第5章 COVID-19影響分析

  • COVID-19に関する研究開発

第6章 世界のワクチン販売市場の見通し

  • 市場概要
  • 市場概要
  • 金額ベースの市場
  • 疾患タイプ別
  • ウイルス性疾患別
  • ワクチンタイプ別
    • 組換え/共役/サブユニットセグメントの主要シェアの保持
    • 不活化ワクチン
    • トキソイドワクチン
    • サブユニットワクチン
    • 共役ワクチン
    • 組換えベクターワクチン
    • DNAワクチン
    • RNAワクチン
    • アジュバントおよび賦形剤
    • 病原体成分
    • 粒子状アジュバント
    • その他/組み合わせワクチン
  • 細菌性疾患別
  • 流通チャネル別
  • 年齢層別
    • 小児用ワクチン
    • 小児用ワクチンの動向
    • 出生前ワクチン

第7章 北米市場の見通し

  • 市場概要
  • 金額ベースの市場
  • 国別:市場の内訳
  • 米国
  • カナダ
  • 疾患タイプ別
  • ウイルス性疾患別
  • ワクチンタイプ別
  • 細菌性疾患別
  • 流通チャネル別
  • 年齢層別

第8章 欧州市場の見通し

  • 市場概要
  • 金額ベースの市場
  • 国別:市場の内訳
  • ロシア
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • その他の国
  • 疾患タイプ別
  • ウイルス性疾患別
  • ワクチンタイプ別
  • 細菌性疾患別
  • 流通チャネル別
  • 年齢層別

第9章 アジア太平洋地域市場の見通し

  • 市場概要
  • 金額ベースの市場
  • 国別:市場の内訳
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • その他の国
  • 疾患タイプ別
  • ウイルス性疾患別
  • ワクチンタイプ別
  • 細菌性疾患別
  • 流通チャネル別
  • 年齢層別

第10章 中東およびアフリカ市場の見通し

  • 市場概要
  • 金額ベースの市場
  • 国別:市場の内訳
  • トルコ
  • サウジアラビア
  • 南アフリカ
  • イラン
  • アラブ首長国連邦
  • その他の国
  • 疾患タイプ別
  • ウイルス性疾患別
  • ワクチンタイプ別
  • 細菌性疾患別
  • 流通チャネル別
  • 年齢層別

第11章 ラテンアメリカ市場の見通し

  • 市場概要
  • 金額ベースの市場
  • 国別:市場の内訳
  • ブラジル
  • メキシコ
  • ナイジェリア
  • その他の国
  • 疾患タイプ別
  • ウイルス性疾患別
  • ワクチンタイプ別
  • 細菌性疾患別
  • 流通チャネル別
  • 年齢層別

第12章 研究開発のワクチン

  • デングワクチン調査
    • ワクチン開発の状況
    • ワクチン開発への課題
    • WHOの活動
  • マラリアワクチン
    • ワクチン開発の状況
  • HIVワクチンの開発
  • 髄膜炎ワクチンの開発
  • インフルエンザワクチン
    • インフルエンザワクチンの開発
    • ワクチン開発の状況
    • ワクチン開発への課題
  • 結核ワクチンの開発
  • ジカウイルスワクチン製品開発
    • ジカワクチン開発の技術ロードマップ
  • グループA連鎖球菌
  • RSVワクチンの研究開発

第13章 主要企業プロファイル

  • 最近の技術と企業
  • 市場シェア
  • AstraZeneca
    • 事業概要
    • 企業の財務プロファイル
    • 製品とサービス提供
    • 最近の動向
  • Johnson & Johnson
  • Bavarian Nordic
  • Merck & Co.
  • Takeda Pharmaceutical Company
  • Roche Holding AG
  • GlaxoSmithKline PLC (GSK)
  • Bayer Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Emergent BioSolutions Inc.
  • Fresenius SE & Co KGaA
  • Sanofi
  • BiondVaxPharmaceuticals Ltd.

第14章 結論と提言

目次
Product Code: PHA0809

Vaccine Sales Market our new study reveals trends, R&D progress, and predicted revenues

Where is the Vaccines market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 602 pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccines Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry.

Report Scope

  • Disease Type
    • Viral Diseases
    • Bacterial Diseases
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus
    • Measles/Mumps/Rubella
    • Rotavirus
    • Other Viral Diseases
  • Bacterial Disease
    • Pneumococcal Disease
    • Meningococcal Disease
    • Diphtheria/Tetanus/Pertussis
    • Other Bacterial Disease
  • Type Vaccines
    • Recombinant/Conjugate/Subunit
    • Inactivated
    • Live Attenuated
    • Toxoid
  • Distribution Channel
    • Hospital & Retail Pharmacies
    • Government Suppliers
    • Other Distribution Channel
  • Age Group
    • Paediatrics
    • Adults
    • Other Age Groups

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Rest of Middle East and Africa
  • Latin America
    • Brazil
    • Mexico
    • Nigeria
    • Rest of Latin America

Table of Contents

1. Report Overview

  • 1.1 Why You Should Buy This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report Include:
  • 1.4 Who is This Report For?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Data Sources
  • 1.6 Market Evaluation & Forecasting Methodology
  • 1.7 COIVD-19 Impact Recovery Pattern Analysis
    • 1.7.1 V-Shaped Recovery
    • 1.7.2 U-Shaped Recovery
    • 1.7.3 W-Shaped Recovery
    • 1.7.4 L-Shaped Recovery
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Executive Summary

  • 2.1.1 Growing Demand for Bacterial Type to Dominate the Market
    • 2.1.1.1 Due to higher sales of pneumococcal, meningitis and DTP worldwide, the segment of bacterial diseases has a dominant market share
  • 2.1.2 By Age Group Analysis
  • 2.1.3 By Distribution Channel Analysis
  • 2.1.4 Regional Market Insight

3. Vaccine Industry Overview

  • 3.1 Industry Definitions
  • 3.2 Immune System and Vaccines
  • 3.3 How Vaccines Work
  • 3.4 Types of Immunity
    • 3.4.1 Active Immunity
    • 3.4.2 Passive Immunity
    • 3.4.3 Advantages of Vaccination
  • 3.5 History of Vaccines
  • 3.6 Rapid Manufacturing for Pandemics
    • 3.6.1 Types of Vaccine Manufacturing Methods

4. Market Dynamics

  • 4.1 Vaccine Development and Distribution Amid the COVID-19 Pandemic
  • 4.2 Market Growth Driving Factors
    • 4.2.1 Growing Vaccines Supply by UNICEF, WHO, PAHO to Aid Immunization Process
    • 4.2.2 Strong Supply Backed Up by Robust R&D to Drive the Market
    • 4.2.3 Competitive Pipeline to Expand the Market Value During the Forecast Period
    • 4.2.4 Technological Advancements such as Rapid Manufacturing and Others
    • 4.2.5 Rising Immunization Across the Globe
    • 4.2.6 Government Support for Vaccine Development
  • 4.3 Market Growth Restraining Factors
    • 4.3.1 High Cost Associated with Vaccine Dose to Limit Adoption
    • 4.3.2 Lack of Awareness in Low-Income Countries
    • 4.3.1 High Prices of Vaccines
    • 4.3.1 Rising Concerns of Associated Risk Factors
    • 4.3.2 Inadequate Vaccine Supply
  • 4.4 Growth Opportunities in the Global Market
    • 4.4.1 RNA Vaccination
    • 4.4.2 Rise of Antibiotic Resistance
    • 4.4.3 Current Situation
    • 4.4.4 Development and Launch of New Vaccines
    • 4.4.5 Increased R&D Efforts
    • 4.4.6 Increased Demand from Emerging Markets
    • 4.4.7 Government Initiatives for Increased Immunizations
    • 4.4.8 Global Alliance for Vaccines and Immunization (GAVI)
    • 4.4.9 Improving access to sustainable immunization services.
    • 4.4.10 Undulating Demand
    • 4.4.11 Supply Restraints
    • 4.4.12 Funding Trends
    • 4.4.13 Protecting the Workforce of an Economy
  • 4.5 SWOT Analysis of the World Human Vaccines Market
    • 4.5.1 Strengths
    • 4.5.2 Weaknesses
    • 4.5.3 Opportunities
    • 4.5.4 Threats
  • 4.6 STEP Analysis of the World Human Vaccines Industry and Market
    • 4.6.1 Social Factors
    • 4.6.2 Technological Forces
    • 4.6.3 Economic Factors
    • 4.6.4 Political Factors

5. COVID-19 Impact Analysis

  • 5.1 Research and Development on COVID-19

6. Global Vaccines Sales Market Outlook

  • 6.1 Market Overview
  • 6.2 Market in Terms of Value
    • 6.2.1 Market in Terms of Value (Normal Recovery)
    • 6.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.2.4 Market in Terms of Value (U-Shaped Recovery)
  • 6.3 Global Market Breakdown by Region
      • 6.3.1.1 North America is expected to dominate the global market during the forecast period
    • 6.3.1 Market in Terms of Value (Normal Recovery)
    • 6.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.4 Global Market Breakdown by Disease Type
      • 6.4.1.1 Bacterial Diseases the segment held the significant share in the overall market and is expected to offer an opportunity throughout the forecast period
    • 6.4.1 Market in Terms of Value (Normal Recovery)
    • 6.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.5 Global Market Breakdown by Viral Diseases
      • 6.5.1.1 Hepatitis Segment is expected to have the highest CAGR during forecast period.
    • 6.5.1 Human Diseases
    • 6.5.1 Market in Terms of Value (Normal Recovery)
    • 6.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.6 Global Market Breakdown by Vaccine Type
    • 6.6.1 Recombinant/Conjugate/Subunit the segment held the significant share
    • 6.6.2 Inactivated (Killed) Vaccines
    • 6.6.3 Toxoid Vaccines
    • 6.6.4 Subunit Vaccines
    • 6.6.5 Conjugate Vaccines
    • 6.6.6 Recombinant Vector Vaccines
    • 6.6.7 DNA Vaccines
    • 6.6.8 RNA Vaccines
    • 6.6.9 Adjuvants and Excipients
    • 6.6.10 Pathogen Components
    • 6.6.11 Particulate Adjuvants
    • 6.6.12 Other/Combination Vaccines
    • 6.6.13 Market in Terms of Value (Normal Recovery)
    • 6.6.14 Market in Terms of Value (V-Shaped Recovery)
    • 6.6.15 Market in Terms of Value (W-Shaped Recovery)
    • 6.6.16 Market in Terms of Value (U-Shaped Recovery)
    • 6.6.17 Market in Terms of Value (L-Shaped Recovery)
  • 6.7 Global Market Breakdown by Bacterial Disease
      • 6.7.1.1 Pneumococcal Disease is expected to offer an opportunity throughout the forecast period
    • 6.7.1 Market in Terms of Value (Normal Recovery)
    • 6.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.8 Global Market Breakdown by Distribution Channel
      • 6.8.1.1 A dominant share of the income is anticipated for hospital and retail pharmacies
    • 6.8.1 Market in Terms of Value (Normal Recovery)
    • 6.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.9 Global Market Breakdown by Age Group
    • 6.9.1 Pediatric Vaccines
    • 6.9.2 Paediatric Vaccine Trends
    • 6.9.3 Prenatal Vaccines
    • 6.9.4 Market in Terms of Value (Normal Recovery)
    • 6.9.5 Market in Terms of Value (V-Shaped Recovery)
    • 6.9.6 Market in Terms of Value (W-Shaped Recovery)
    • 6.9.7 Market in Terms of Value (U-Shaped Recovery)
    • 6.9.8 Market in Terms of Value (L-Shaped Recovery)

7. North America Vaccines Sales Market Outlook

    • 7.1.1 Growth attributed to vaccination compulsion or mandate
  • 7.1 North America Market Overview
  • 7.2 North America Market in Terms of Value
    • 7.2.1 Market in Terms of Value (Normal Recovery)
    • 7.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.3 North America Market Breakdown by Country
    • 7.3.1 Market in Terms of Value (Normal Recovery)
    • 7.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.4 U.S. Vaccine Sales Market Outlook
      • 7.4.1.1 The country is expected to offer an opportunity throughout the forecast period
    • 7.4.1 Market in Terms of Value (Normal Recovery)
    • 7.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.5 Canada Vaccine Sales Market Outlook
      • 7.5.1.1 Market is supported by consistent and sustained funding of immunization programs
    • 7.5.1 Market in Terms of Value (Normal Recovery)
    • 7.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.6 North America Market Breakdown by Disease Type
    • 7.6.1 Market in Terms of Value (Normal Recovery)
    • 7.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.7 North America Market Breakdown by Viral Diseases
    • 7.7.1 Market in Terms of Value (Normal Recovery)
    • 7.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.8 North America Market Breakdown by Vaccine Type
    • 7.8.1 Market in Terms of Value (Normal Recovery)
    • 7.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.9 North America Market Breakdown by Bacterial Disease
    • 7.9.1 Market in Terms of Value (Normal Recovery)
    • 7.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.10 North America Market Breakdown by Distribution Channel
    • 7.10.1 Market in Terms of Value (Normal Recovery)
    • 7.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.11 North America Market Breakdown by Age Group
    • 7.11.1 Market in Terms of Value (Normal Recovery)
    • 7.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.11.5 Market in Terms of Value (L-Shaped Recovery)

8. Europe Vaccines Sales Market Outlook

  • 8.1 Europe Market Overview
    • 8.1.1 A considerable growth in the vaccine market is expected in the European region.
  • 8.2 Europe Market in Terms of Value
    • 8.2.1 Market in Terms of Value (Normal Recovery)
    • 8.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.3 Europe Market Breakdown by Country
    • 8.3.1 Market in Terms of Value (Normal Recovery)
    • 8.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.4 Russia Vaccine Sales Market Outlook
      • 8.4.1.1 The Russian Federation has purchased over 90% of the total supply of the vaccines in the market
    • 8.4.1 Market in Terms of Value (Normal Recovery)
    • 8.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.5 Germany Vaccine Sales Market Outlook
    • 8.5.1.1 Germany is expected to offer an opportunity throughout the forecast period.
    • 8.5.1 Market in Terms of Value (Normal Recovery)
    • 8.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.6 UK Vaccine Sales Market Outlook
      • 8.6.1.1 The U.K. is one of the major contributors to the vaccine market
    • 8.6.1 Market in Terms of Value (Normal Recovery)
    • 8.6.1 Market in Terms of Value (V-Shaped Recovery)
    • 8.6.2 Market in Terms of Value (W-Shaped Recovery)
    • 8.6.3 Market in Terms of Value (U-Shaped Recovery)
    • 8.6.4 Market in Terms of Value (L-Shaped Recovery)
  • 8.7 France Vaccine Sales Market Outlook
      • 8.7.1.1 France is one of the major countries to produce vaccines
    • 8.7.1 Market in Terms of Value (Normal Recovery)
    • 8.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.8 Italy Vaccine Sales Market Outlook
      • 8.8.1.1 Italy is the fourth largest market for human vaccines within Europe
    • 8.8.1 Market in Terms of Value (Normal Recovery)
    • 8.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.9 Rest of Europe Vaccine Sales Market Outlook
    • 8.9.1 Market in Terms of Value (Normal Recovery)
    • 8.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.10 Europe Market Breakdown by Disease Type
    • 8.10.1 Market in Terms of Value (Normal Recovery)
    • 8.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.11 Europe Market Breakdown by Viral Disease
    • 8.11.1 Market in Terms of Value (Normal Recovery)
    • 8.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.12 Europe Market Breakdown by Vaccine Type
    • 8.12.1 Market in Terms of Value (Normal Recovery)
    • 8.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.13 Europe Market Breakdown by Bacterial Disease
    • 8.13.1 Market in Terms of Value (Normal Recovery)
    • 8.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.14 Europe Market Breakdown by Distribution Channel
    • 8.14.1 Market in Terms of Value (Normal Recovery)
    • 8.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.15 Europe Market Breakdown by Age Group
    • 8.15.1 Market in Terms of Value (Normal Recovery)
    • 8.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.15.5 Market in Terms of Value (L-Shaped Recovery)

9. Asia-Pacific Vaccines Sales Market Outlook

  • 9.1 Asia-Pacific Market Overview
  • 9.2 Asia-Pacific Market in Terms of Value
    • 9.2.1 Market in Terms of Value (Normal Recovery)
    • 9.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.3 Asia-Pacific Market Breakdown by Country
    • 9.3.1 Market in Terms of Value (Normal Recovery)
    • 9.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.4 China Vaccine Sales Market Outlook
      • 9.4.1.1 Growth prospects remain strong in the country
    • 9.4.1 Market in Terms of Value (Normal Recovery)
    • 9.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.5 Japan Vaccine Sales Market Outlook
      • 9.5.1.1 Japan is expected to offer an opportunity throughout the forecast period
    • 9.5.1 Market in Terms of Value (Normal Recovery)
    • 9.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.6 India Vaccine Sales Market Outlook
      • 9.6.1.1 The prevalence of the diseases has been quite high in India, which is driving the market growth
    • 9.6.1 Market in Terms of Value (Normal Recovery)
    • 9.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.7 South Korea Vaccine Sales Market Outlook
      • 9.7.1.1 Korea has been importing all demand for this vaccine due to a lack of homegrown technology to develop a vaccine locally
    • 9.7.1 Market in Terms of Value (Normal Recovery)
    • 9.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.8 Australia Vaccine Sales Market Outlook
      • 9.8.1.1 Australia is on track for a record number of flu vaccinations
    • 9.8.1 Market in Terms of Value (Normal Recovery)
    • 9.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.9 Rest of Asia-Pacific Vaccine Sales Market Outlook
    • 9.9.1 Market in Terms of Value (Normal Recovery)
    • 9.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.10 Asia-Pacific Market Breakdown by Disease Type
    • 9.10.1 Market in Terms of Value (Normal Recovery)
    • 9.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.11 Asia-Pacific Market Breakdown by Viral Diseases
    • 9.11.1 Market in Terms of Value (Normal Recovery)
    • 9.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.12 Asia-Pacific Market Breakdown by Vaccine Type
    • 9.12.1 Market in Terms of Value (Normal Recovery)
    • 9.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.13 Asia-Pacific Market Breakdown by Bacterial Disease
    • 9.13.1 Market in Terms of Value (Normal Recovery)
    • 9.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.14 Asia-Pacific Market Breakdown by Distribution Channel
    • 9.14.1 Market in Terms of Value (Normal Recovery)
    • 9.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.15 Asia-Pacific Market Breakdown by Age Group
    • 9.15.1 Market in Terms of Value (Normal Recovery)
    • 9.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.15.5 Market in Terms of Value (L-Shaped Recovery)

10. Middle East & Africa Vaccines Sales Market Outlook

  • 10.1 Middle East & Africa Market Overview
  • 10.2 Middle East & Africa Market in Terms of Value
    • 10.2.1 Market in Terms of Value (Normal Recovery)
    • 10.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.3 Middle East & Africa Market Breakdown by Country
    • 10.3.1 Market in Terms of Value (Normal Recovery)
    • 10.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.4 Turkey Vaccine Sales Market Outlook
    • 10.4.1 Market in Terms of Value (Normal Recovery)
    • 10.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.5 Saudi Arabia Vaccine Sales Market Outlook
      • 10.5.1.1 Healthcare is the third largest beneficiary behind education and military
    • 10.5.1 Market in Terms of Value (Normal Recovery)
    • 10.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.6 South Africa Vaccine Sales Market Outlook
      • 10.6.1.1 Pneumonia vaccine alone used up 40% of South Africa's total budget for vaccines
    • 10.6.1 Market in Terms of Value (Normal Recovery)
    • 10.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.7 Iran Vaccine Sales Market Outlook
      • 10.7.1.1. Iran's vaccine industry, has a long history and international reputation
    • 10.7.1 Market in Terms of Value (Normal Recovery)
    • 10.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.8 UAE Vaccine Sales Market Outlook
    • 10.8.1 Market in Terms of Value (Normal Recovery)
    • 10.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.9 Rest of Middle East & Africa Vaccine Sales Market Outlook
    • 10.9.1 Market in Terms of Value (Normal Recovery)
    • 10.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.10 Middle East & Africa Market Breakdown by Disease Type
    • 10.10.1 Market in Terms of Value (Normal Recovery)
    • 10.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.11 Middle East & Africa Market Breakdown by Viral Diseases
    • 10.11.1 Market in Terms of Value (Normal Recovery)
    • 10.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.12 Middle East & Africa Market Breakdown by Vaccine Type
    • 10.12.1 Market in Terms of Value (Normal Recovery)
    • 10.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.13 Middle East & Africa Market Breakdown by Bacterial Disease
    • 10.13.1 Market in Terms of Value (Normal Recovery)
    • 10.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.14 Middle East & Africa Market Breakdown by Distribution Channel
    • 10.14.1 Market in Terms of Value (Normal Recovery)
    • 10.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.15 Middle East & Africa Market Breakdown by Age Group
    • 10.15.1 Market in Terms of Value (Normal Recovery)
    • 10.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.15.5 Market in Terms of Value (L-Shaped Recovery)

11. Latin America Vaccines Sales Market Outlook

  • 11.1 Latin America Market Overview
  • 11.2 Latin America Market in Terms of Value
    • 11.2.1 Market in Terms of Value (Normal Recovery)
    • 11.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.3 Latin America Market Breakdown by Country
    • 11.3.1 Market in Terms of Value (Normal Recovery)
    • 11.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.4 Brazil Vaccine Sales Market Outlook
      • 11.4.1.1 The Brazilian human vaccines market is the largest in Latin America
    • 11.4.1 Market in Terms of Value (Normal Recovery)
    • 11.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.5 Mexico Vaccine Sales Market Outlook
    • 11.5.1 Market in Terms of Value (Normal Recovery)
    • 11.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.6 Nigeria Vaccine Sales Market Outlook
      • 11.6.1.1 The market is expected to grow at a decent growth rate during forecast period
    • 11.6.1 Market in Terms of Value (Normal Recovery)
    • 11.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.7 Rest of Latin America Vaccine Sales Market Outlook
    • 11.7.1 Market in Terms of Value (Normal Recovery)
    • 11.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.8 Latin America Market Breakdown by Disease Type
    • 11.8.1 Market in Terms of Value (Normal Recovery)
    • 11.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.9 Latin America Market Breakdown by Viral Diseases
    • 11.9.1 Market in Terms of Value (Normal Recovery)
    • 11.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.10 Latin America Market Breakdown by Vaccine Type
    • 11.10.1 Market in Terms of Value (Normal Recovery)
    • 11.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.11 Latin America Market Breakdown by Bacterial Diseases
    • 11.11.1 Market in Terms of Value (Normal Recovery)
    • 11.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.12 Latin America Market Breakdown by Distribution Channel
    • 11.12.1 Market in Terms of Value (Normal Recovery)
    • 11.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.13 Latin America Market Breakdown by Age Group
    • 11.13.1 Market in Terms of Value (Normal Recovery)
    • 11.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.13.5 Market in Terms of Value (L-Shaped Recovery)

12. Vaccines Under Research & Development

  • 12.1 Dengue Vaccine Research
    • 12.1.1 Status of vaccine development
    • 12.1.2 Challenges to Vaccine Development
    • 12.1.3 WHO activities
  • 12.2 Malaria vaccines
    • 12.2.1 Status of vaccine development
  • 12.3 HIV Vaccine Development
  • 12.4 Meningitis Vaccine Development
  • 12.5 Influenza vaccines
    • 12.5.1 Influenza Vaccine Development
    • 12.5.2 Status of Vaccine Development
    • 12.5.3 Challenges to Vaccine Development
  • 12.6 Tuberculosis Vaccine Development
  • 12.7 Zika Virus Vaccine Product Development
    • 12.7.1 Technical roadmap for Zika vaccine development
  • 12.8 Group A Streptococcus
  • 12.9 RSV Vaccine Research And Development

13. Leading Company Profiles

  • 13.1 Recent Technologies and Companies
  • 13.2 Market Share
  • 13.3 AstraZeneca
    • 13.3.1 AstraZeneca: Business Overview
    • 13.3.2 AstraZeneca: Company Financial Profile
    • 13.3.3 AstraZeneca: Product and Service Offerings
    • 13.3.4 AstraZeneca: Recent Developments
  • 13.4 Johnson & Johnson
    • 13.4.1 Johnson & Johnson: Business Overview
    • 13.4.2 Johnson & Johnson: Company Financial Profile
    • 13.4.3 Johnson & Johnson: Product and Service Offerings
    • 13.4.4 Johnson & Johnson: Recent Developments
  • 13.5 Bavarian Nordic
    • 13.5.1 Bavarian Nordic: Business Overview
    • 13.5.2 Bavarian Nordic: Company Financial Profile
    • 13.5.3 Bavarian Nordic: Product and Service Offerings
    • 13.5.4 Bavarian Nordic: Recent Developments
  • 13.6 Merck & Co.
    • 13.6.1 Merck & Co.: Business Overview
    • 13.6.2 Merck & Co.: Company Financial Profile
    • 13.6.3 Merck & co.: Product and Service Offerings
    • 13.6.4 Merck & co.: Recent Developments
  • 13.7 Takeda Pharmaceutical Company
    • 13.7.1 Takeda Pharmaceutical Company: Business Overview
    • 13.7.2 Takeda Pharmaceutical Company: Company Financial Profile
    • 13.7.3 Takeda Pharmaceutical Company: Product and Service Offerings
    • 13.7.4 Takeda Pharmaceutical Company: Recent Developments
  • 13.8 Roche Holding AG
    • 13.8.1 Roche Holding AG: Business Overview
    • 13.8.2 Roche Holding AG: Company Financial Profile
    • 13.8.3 Roche Holding AG: Product and Service Offerings
    • 13.8.4 Roche Holding AG: Recent Developments
  • 13.9 GlaxoSmithKline PLC (GSK)
    • 13.9.1 GlaxoSmithKline PLC (GSK): Business Overview
    • 13.9.2 GlaxoSmithKline PLC (GSK): Company Financial Profile
    • 13.9.3 GlaxoSmithKline PLC (GSK): Product and Service Offerings
    • 13.9.4 GlaxoSmithKline PLC (GSK): Recent Developments
  • 13.10 Bayer Inc.
    • 13.10.1 Bayer Inc.: Business Overview
    • 13.10.2 Bayer Inc.: Company Financial Profile
    • 13.10.3 Bayer Inc.: Product and Service Offerings
    • 13.10.4 Bayer Inc.: Recent Developments
  • 13.11 Eli Lilly and Company
    • 13.11.1 Eli Lilly and Company: Business Overview
    • 13.11.2 Eli Lilly and Company: Company Financial Profile
    • 13.11.3 Eli Lilly and Company: Product and Service Offerings
    • 13.11.4 Eli Lilly and Company: Recent Developments
  • 13.12 Bristol-Myers Squibb
    • 13.12.1 Bristol-Myers Squibb: Business Overview
    • 13.12.2 Bristol-Myers Squibb: Company Financial Profile
    • 13.12.3 Bristol-Myers Squibb: Product and Service Offerings
    • 13.12.4 Bristol-Myers Squibb: Recent Developments
  • 13.13 Pfizer Inc.
    • 13.13.1 Pfizer Inc.: Business Overview
    • 13.13.2 Pfizer Inc.: Company Financial Profile
    • 13.13.3 Pfizer Inc.: Product and Service Offerings
    • 13.13.4 Pfizer Inc.: Recent Developments
  • 13.14 Emergent BioSolutions Inc.
    • 13.14.1 Emergent BioSolutions Inc.: Business Overview
    • 13.14.2 Emergent BioSolutions Inc.: Company Financial Profile
    • 13.14.3 Emergent BioSolutions Inc.: Product and Service Offerings
    • 13.14.4 Emergent BioSolutions Inc.: Recent Developments
  • 13.15 Fresenius SE & Co KGaA
    • 13.15.1 Fresenius SE & Co KGaA: Business Overview
    • 13.15.2 Fresenius SE & Co KGaA: Company Financial Profile
    • 13.15.3 Fresenius SE & Co KGaA: Product and Service Offerings
    • 13.15.4 Fresenius SE & Co KGaA: Recent Developments
  • 13.16 Sanofi
    • 13.16.1 Sanofi: Business Overview
    • 13.16.2 Sanofi: Company Financial Profile
    • 13.16.3 Sanofi: Product and Service Offerings
    • 13.16.4 Sanofi: Recent Developments
  • 13.17 BiondVaxPharmaceuticals Ltd.
    • 13.17.1 BiondVax Pharmaceuticals Ltd.: Business Overview
    • 13.17.2 BiondVax Pharmaceuticals Ltd.: Company Financial Profile
    • 13.17.3 BiondVax Pharmaceuticals Ltd.: Product and Service Offerings
    • 13.17.4 BiondVax Pharmaceuticals Ltd.: Recent Developments

14. Conclusion & Recommendations

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.